Epigenetic Regulation in Primary CNS Tumors: An Opportunity to Bridge Old and New WHO Classifications

• Published in: Cancers Vol. 15; no. 9; p. 2511
• Main Authors: Dang, Danielle D, Rosenblum, Jared S, Shah, Ashish H, Zhuang, Zhengping, Doucet-O'Hare, Tara T
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.04.2023; MDPI
• Subjects: Analysis; atypical teratoid rhabdoid tumor; Behavior; Biology; Cancer; Central nervous system; central nervous system tumors; Chromatin; Chromatin remodeling; Classification; Classification schemes; DNA methylation; endogenous retroviruses; Epigenetic inheritance; Epigenetics; Gene expression; HERVK; Histones; Malignancy; Medical prognosis; Methylation; Molecular modelling; Mutation; Open reading frames; Proteins; Review; Sucrose; SWI/SNF; Therapeutic targets; Tumorigenesis; Tumors; meningioma; World Health Organization; glioblastoma; endogenous retroviruses; central nervous system tumors; SWI/SNF; chromatin remodeling; atypical teratoid rhabdoid tumor; HERVK; schwannoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15092511

Originally approved in 1979, a specific grading classification for central nervous system (CNS) tumors was devised by the World Health Organization (WHO) in an effort to guide cancer treatment and better understand prognosis. These "blue books" have since undergone several iterations based on tumor location, advancements in histopathology, and most recently, diagnostic molecular pathology in its fifth edition. As new research methods have evolved to elucidate complex molecular mechanisms of tumorigenesis, a need to update and integrate these findings into the WHO grading scheme has become apparent. Epigenetic tools represent an area of burgeoning interest that encompasses all non-Mendelian inherited genetic features affecting gene expression, including but not limited to chromatin remodeling complexes, DNA methylation, and histone regulating enzymes. The SWItch/Sucrose non-fermenting (SWI/SNF) chromatin remodeling complex is the largest mammalian family of chromatin remodeling proteins and is estimated to be altered in 20-25% of all human malignancies; however, the ways in which it contributes to tumorigenesis are not fully understood. We recently discovered that CNS tumors with SWI/SNF mutations have revealed an oncogenic role for endogenous retroviruses (ERVs), remnants of exogenous retroviruses that integrated into the germline and are inherited like Mendelian genes, several of which retain open reading frames for proteins whose expression putatively contributes to tumor formation. Herein, we analyzed the latest WHO classification scheme for all CNS tumors with documented SWI/SNF mutations and/or aberrant ERV expression, and we summarize this information to highlight potential research opportunities that could be integrated into the grading scheme to better delineate diagnostic criteria and therapeutic targets.